Potential Public Health Impact of Age-Related Eye Disease Study Results: AREDS Report No. 11
Open accessAbstract
OBJECTIVE: To estimate the potential public health impact of the findings of the Age-Related Eye Disease Study (AREDS) on reducing the number of persons developing advanced age-related macular degeneration (AMD) during the next 5 years in the United States. METHODS: The AREDS clinical trial provides estimates of AMD progression rates and of reduction in risk of developing advanced AMD when a high-dose nutritional supplement of antioxidants and zinc is used. These results are applied to estimates of the US population at risk, to estimate the number of people who would potentially avoid advanced AMD during 5 years if those at risk were to take a supplement such as that used in AREDS. RESULTS: An estimated 8 million persons at least 55 years old in the United States have monocular or binocular intermediate AMD or monocular advanced AMD. They are considered to be at high risk for advanced AMD and are those for whom the AREDS formulation should be considered. Of these people, 1.3 million would develop advanced AMD if no treatment were given to reduce their risk. If all of these people at risk received supplements such as those used in AREDS, more than 300,000 (95% confidence interval, 158,000-487,000) of them would avoid advanced AMD and any associated vision loss during the next 5 years. CONCLUSION: If people at high risk for advanced AMD received supplements such as those suggested by AREDS results, the potential impact on public health in the United States would be considerable during the next 5 years.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The AREDS demonstrated that zinc-antioxidant supplements prevent or delay progression of early AMD to late AMD in high-risk patients.
“The AREDS demonstrated the efficacy of zinc-antioxidant supplements for preventing or delaying progression of early AMD to late AMD in patients who are at high risk (Bressler et al., 2003).”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Bressler et al., 2003
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
(2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.10.1417 · Cited by 3,285 · see citing works
Prevalence of age-related maculopathy
Klein, R., Klein, B. E. K., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31871-8 · Cited by 1,845 · see citing works
Self-citationRacial differences in the prevalence of age-related macular degeneration
Friedman, D. S., Katz, J., Bressler, N. M., Rahmani, B., & Tielsch, J. M. (1999) · Ophthalmology · doi:10.1016/s0161-6420(99)90267-1 · Cited by 304 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · see citing works
Age-related macular degeneration
Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379 · see citing works
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007176.pub2 · Cited by 924 · see citing works
Molecular pathology of age-related macular degeneration
Ding, X., Patel, M., & Chan, C.-C. (2009) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.10.001 · Cited by 582 · see citing works
Age-related macular degeneration
Coleman, H. R., Chan, C.-C., Ferris, F. L., & Chew, E. Y. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61759-6 · Cited by 542 · see citing works
Self-citationSeddon, J. M. (2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.6.774 · Cited by 354 · see citing works
Self-citationPegaptanib Sodium for Neovascular Age-Related Macular Degeneration
D’Amico, D. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.02.027 · Cited by 260 · see citing works
TACHYPHYLAXIS AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
FOROOGHIAN, F., CUKRAS, C., MEYERLE, C. B., CHEW, E. Y., & WONG, W. T. (2009) · Retina · doi:10.1097/iae.0b013e3181a2c1c3 · Cited by 179 · see citing works
Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation
Gasperini, J. L., Fawzi, A. A., Khondkaryan, A., Lam, L., Chong, L. P., Eliott, D., Walsh, A. C., Hwang, J., & Sadda, S. R. (2012) · British Journal of Ophthalmology · doi:10.1136/bjo.2011.204685 · Cited by 175 · see citing works
Sun~er, I. J., Kokame, G. T., Yu, E., Ward, J., Dolan, C., & Bressler, N. M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3225 · Cited by 170 · see citing works
Self-citationKeane, P. A., Liakopoulos, S., Ongchin, S. C., Heussen, F. M., Msutta, S., Chang, K. T., Walsh, A. C., & Sadda, S. R. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-1689 · Cited by 145 · see citing works
Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab
Eghøj, M. S., & Sørensen, T. L. (2012) · British Journal of Ophthalmology · doi:10.1136/bjo.2011.203893 · Cited by 143 · see citing works
Chen, L.-J., Ito, S., Kai, H., Nagamine, K., Nagai, N., Nishizawa, M., Abe, T., & Kaji, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-03788-5 · Cited by 112 · see citing works
Overview of progress in the epidemiology of age-related macular degeneration
Klein, R. (2007) · Ophthalmic Epidemiology · doi:10.1080/09286580701344381 · Cited by 110 · see citing works
Self-citationApolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD)
Baird, P. N., Richardson, A. J., Robman, L. D., Dimitrov, P. N., Tikellis, G., McCarty, C. A., & Guymer, R. H. (2006) · Human Mutation · doi:10.1002/humu.20288 · Cited by 105 · see citing works
Baird, P. N., Robman, L. D., Richardson, A. J., Dimitrov, P. N., Tikellis, G., McCarty, C. A., & Guymer, R. H. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn018 · Cited by 90 · see citing works
Hallam, D., Collin, J., Bojic, S., Chichagova, V., Buskin, A., Xu, Y., Lafage, L., Otten, E. G., Anyfantis, G., Mellough, C., et al. (2017) · Stem Cells · doi:10.1002/stem.2708 · Cited by 75 · see citing works
Laser Treatment in Patients with Bilateral Large Drusen
(2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.08.015 · Cited by 71 · see citing works
Orlin, A., Hadley, D., Chang, W., Ho, A. C., Brown, G., Kaiser, R. S., Regillo, C. D., Godshalk, A. N., Lier, A., Kaderli, B., et al. (2012) · Retina · doi:10.1097/iae.0b013e31822a2c7c · Cited by 60 · see citing works
Cerniauskas, E., Kurzawa-Akanbi, M., Xie, L., Hallam, D., Moya-Molina, M., White, K., Steel, D., Doherty, M., Whitfield, P., Al-Aama, J., et al. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0211 · Cited by 58 · see citing works
Bioactive lipids and pathological retinal angiogenesis
Elmasry, K., Ibrahim, A. S., Abdulmoneim, S., & Al‐Shabrawey, M. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14507 · Cited by 39 · see citing works
- Authors
- Bressler, N. M., Sb, B., Congdon, N. G., Ferris, F. L., Friedman, D. S., Klein, R., Lindblad, A. S., Milton, R. C., & Seddon, J. M.
- Affiliations
- Emmes (United States) (US)
- Venue
- Archives of Ophthalmology
- Publisher
- American Medical Association (AMA)
- Published
- 2003-11-01
- Volume
- 121
- Issue
- 11
- Pages
- 1621
- ISSN
- 0003-9950 (ISSN-L)
- PMC
- PMC1473209
- OpenAlex
- W109974915
- Cited by
- 374
- References
- 3
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 5 · 2023: 11 · 2022: 8 · 2021: 10 · 2020: 15 · 2019: 10 · 2018: 19 · 2017: 17 · 2016: 13 · 2015: 17 · 2014: 13 · 2013: 22 · 2012: 19
- FWCI
- 20.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Archives of Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- National Institutes of Health (1z01ey000394-01)
- National Eye Institute (Z01 EY000394-03)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Epidemiology › Ophthalmology and Visual Impairment Studies
- Keywords
- age-related macular degeneration, AREDS, dietary supplements, antioxidants, zinc, AMD progression, blindness prevention, public health impact, intermediate AMD, vulnerable populations
- MeSH terms
- Antioxidants, Ascorbic Acid, Clinical Trials as Topic, Humans, Macular Degeneration, Middle Aged, Public Health, United States, Vision Disorders, Vitamin E, Zinc, Disease Progression, beta Carotene, Dietary Supplements, Risk Reduction Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
